2,232 press releases in English indexed under biotech & pharma.
Dublin, Oct. 20, 2026 -- "Food Biotechnology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, to
SAN FRANCISCO, Oct. 20, 2026 -- AltruBio Inc. ("AltruBio" or "the Company"), a clinical-stage biotech company developing novel immune modulators to address the unmet need in immunological and inflammatory diseases, today announced positive data from its open-label Phase 2a ASCEND UC2a trial evaluating ALTB-268, its first-in-class subcutaneous (SC) PSGL-1 immune modulator, in patients with moderately to severely active ulcerative colitis (UC) who had all failed prior advanced therapies.
Resource Features State-Focused Widgets for Finding Members of Congress, Communicating with Federal & State Lawmakers, and a Community Calendar—Initial Rollout Includes Florida, Illinois, Iowa, Pennsylvania, Texas, and Utah
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe … Continue reading "Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance"
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from … Continue reading "Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting"
Ambrose Healthcare acquires AM-Pharma for up to €161m, adding HPP drug ilofotase alfa to its rare disease pipeline and its first European base in Utrecht.
MARSEILLE, France, October 20, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company ") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update fo
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
SINGAPORE, Oct 20, 2026 - CropLife Asia, the regional association representing the plant science industry, today announced the appointment of three new representatives to its Board of Directors: Sergi Vizoso-Sansano of BASF Agricultural Solutions, Subroto Geed of Corteva Agriscience and Sebastià Pons of FMC. Sergi succeeds Simone Barg as BASF's representative on the Board, Subroto succeeds Brook Cunningham as Corteva's representative, while Sebastià succeeds Rahoul Sawani as FMC's representative. The appointments also coincide with a transition in CropLife Asia's leadership, with Paul Luxton, Head of Asia, Syngenta, formerly VicePresident, assuming the presidency, succeeding Simone Barg. Sergi Vizoso-Sansano leads BASF Agricultural Solutions in Asia Pacific. He brings nearly 30 years of international experience with BASF across Europe and the Americas. Prior to his current role, he served as Senior Vice President, Agricultural Solutions Latin America, based in São Paulo, and also held leadership roles within CropLife associations in Latin America. Subroto Geed is President, Asia Pacific, at Corteva Agriscience, having previously served as the company's Head of South Asia. He brings extensive experience in business leadership, commercial strategy and operations across multiple industries and markets. Prior to joining Corteva, he held senior leadership positions across consumer healthcare, nutrition and beverages, with responsibilities spanning business growth, marketing, supply chain management and organizational development. His cross-sector experience brings a valuable perspective on business transformation, strategic partnerships and market development. Sebastià Pons is the Executive Vice President and President, FMC Eurasia, leading FMC's business across Europe, the Middle East, Africa and Asia Pacific from Geneva. He joined FMC in 2017 and most recently served as President for Europe, Middle East and Africa. Before joining FMC, he spent 20 years with DuPont Crop Protection in regional and global roles across Europe and the United States. He has also served on the Board of CropLife Europe. Paul Luxton has served as Head of Asia at Syngenta since January 2024, overseeing the company's business across key Asian markets, including Southeast Asia, Bangladesh and Korea. He previously led Syngenta's Australia and New Zealand business, having served as Country Head since 2008. With extensive experience in agricultural business leadership and industry engagement, Paul brings a strong understanding of the opportunities and challenges facing agriculture across the region. He previously served as President of CropLife Australia and was Vice-President of CropLife Asia before assuming the presidency. “We are pleased to welcome Sergi, Subroto and Sebastià to the CropLife Asia Board. Their combined international experience and diverse perspectives will strengthen our work to advance science-based policies, responsible stewardship and agricultural innovation across Asia. We also thank our outgoing Board representatives for their contributions and look forward to working with Paul in his role as President,” said Siang Hee Tan, Executive Director of CropLife Asia. CropLife Asia extends its sincere appreciation to Simone Barg for her leadership as President of the Board, and to Brook Cunningham and Rahoul Sawani for their contributions as Board representatives. The association thanks them for their service and commitment to its work across Asia. CropLife Asia Board of Directors The CropLife Asia Board leadership and company representatives are now as follows: Paul Luxton, Syngenta – President Malu Nachreiner, Bayer Crop Science – Treasurer Subroto Geed, Corteva Agriscience – Secretary Dai Ito, Sumitomo Chemical – Member Sergi Vizoso-Sansano, BASF Agricultural Solutions – Member Sebastià Pons, FMC – Member About CropLife Asia CropLife Asia is a non-profit society and the regional organization of CropLife International, the voice of the global plant science industry. We advocate for a safe, secure food supply, and our vision is food security enabled by innovative agriculture. CropLife Asia supports the work of 15 member associations across the continent and is led by six member companies at the forefront of crop protection, seeds and/or biotechnology research and development. For more information, visit us at www.croplifeasia.org. For more information please contact: Cindy Lim Associate Director, Public Affairs & Strategic Partnerships CropLife Asia cindy.lim@croplifeasia.org
New York, New York--(October 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
BOSTON, Oct. 19, 2026 — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics’ portfolio of clinically-differentiated large-bore closure devices for structural heart … Continue reading "Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System"